Jasper Therapeutics (JSPR) Net Income (2020 - 2025)
Jasper Therapeutics (JSPR) posted Net Income of -$15.5 million for Q4 2025, up 17.65% on a QoQ basis from -$18.8 million in Q3 2025, and up 36.33% year-over-year from -$11.4 million in Q4 2024.
Analysis
Jasper Therapeutics (JSPR) Net Income (2020 - 2025) Analysis & Trends
Jasper Therapeutics has reported Net Income for 6 years, with the latest figure at -$15.5 million in Q4 2025.
- On a quarterly basis, Net Income rose 36.33% year-over-year to -$15.5 million in Q4 2025; TTM through Dec 2025 was -$82.1 million, a 15.3% decrease from a year earlier, with the FY2025 full-year figure at -$82.1 million, down 15.4% from the prior year.
- Net Income was -$15.5 million for Q4 2025 at Jasper Therapeutics, up from -$18.8 million in the prior quarter.
- The five-year high for Net Income was $5.5 million in Q1 2021, with the low at -$26.6 million in Q2 2025.
- Average Net Income over 5 years is -$14.4 million, with a median of -$14.1 million recorded in 2024.
- The largest YoY upside for Net Income was 284.79% in 2021 against a maximum downside of 4909.67% in 2021.
- Over 5 years, Net Income stood at -$12.1 million in 2021, then retreated by 10.9% to -$13.4 million in 2022, then fell by 23.08% to -$16.5 million in 2023, then tumbled by 47.64% to -$24.3 million in 2024, then jumped by 36.33% to -$15.5 million in 2025.
- The last three Net Income figures came in at -$15.5 million (Q4 2025), -$18.8 million (Q3 2025), and -$26.6 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Jasper Therapeutics | 20.11 Mn | 20.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -15.50 Mn |
| Sep 30, 2025 | -18.82 Mn |
| Jun 30, 2025 | -26.64 Mn |
| Mar 31, 2025 | -21.18 Mn |
| Dec 31, 2024 | -24.35 Mn |
| Sep 30, 2024 | -18.61 Mn |
| Jun 30, 2024 | -14.58 Mn |
| Mar 31, 2024 | -13.71 Mn |
| Dec 31, 2023 | -16.49 Mn |
| Sep 30, 2023 | -17.93 Mn |
| Jun 30, 2023 | -16.50 Mn |
| Mar 31, 2023 | -12.92 Mn |
| Dec 31, 2022 | -13.40 Mn |
| Sep 30, 2022 | -12.45 Mn |
| Jun 30, 2022 | -11.87 Mn |
| Mar 31, 2022 | -12.78 Mn |
| Dec 31, 2021 | -12.08 Mn |
| Sep 30, 2021 | -10.08 Mn |
| Jun 30, 2021 | -3.57 Mn |
| Mar 31, 2021 | 5.50 Mn |